News

Marc Bonaca, MD, explains the value of new assessments made in the pivotal peripheral artery disease clinical trial.

A cardiologist and wellness expert discusses new findings showing more than one-third of her peers were burnt out from experiences during the pandemic.

The Duke investigators return to discuss the pivotal study of rivaroxaban in peripheral artery disease.

There is no clear threshold for consumption leading to an AFib event.

Patients with a preserved ejection fraction saw a significant reduction in risk for cardiovascular-related adverse events and mortality.

Incidence rates decreased by nearly half after direct-acting antiviral treatment regimen.

A new analysis of the SCORED and SOLOIST trials suggests sotagliflozin could provide substantial benefit for reducing risk of cardiovascular death and worsening heart failure among patients with HFrEF and HFpEF.

New phase 2 data show the potential of the biologic in patients at risk of acute pancreatitis progression, but with a need for better variable understanding.

Investigators discuss recently-published secondary sex-based assessments into PCI treatment, as well as their contribution to cardiovascular research action points that lessen the field's disparities.

The 1-year follow-up of the REALITY trial presented at ACC undermines previously reported 30-day findings showing noninferiority to liberal transfusions.

DARE-19 data show a slight improvement in outcomes among hospitalized COVID-19 patients receiving the SGLT-2 inhibitor—showing the cardiovascular drug class is safe in patients with the pandemic virus.

The SGLT-2 inhibitor drug class is expanding into treatment indications experts could not have predicted. Learn how DAPA-HF contributed to the understanding of dapagliflozin.

A post-hoc analysis sought to elucidate the contradictory results between the STRENGTH and REDUCE-IT trials.

Older patients who maintained the multi-domain rehabilitation program saw improvements in various markers of physical function.

Investigators discuss observed outcomes in females with high-risk PCI treatment, and their continued underrepresentation in pharmacologic studies.

A smaller proportion of patients who used etripamil required an emergency department intervention 5 hours post-administration—compared to placebo users.

Improvements in patient symptoms, function, and quality of life were not sustained once treatment was discontinued.

Though the combination heart failure therapy did provide overall benefit versus ramipril in post-heart attack patients, the rate of events reduced was not considered significant.

The first episode of the Heart Trials podcast series focuses on new ACC 2021 research into aspirin dosages for reduced cardiovascular event risk.

Data suggests that the non-vitamin K antagonist blood thinner may be used as default treatment among post-operative patients in need of oral anticoagulation.

Data show sublingual sufentanil tablets did not affect pain scores, but did benefit patient satisfaction outcomes.

The single 1000 mg dose treats iron deficiency anemia in adult patients.

Vaccinated individuals no longer need to wear masks indoors in accordance with CDC guidance.

Data show a nearly 30% reduction in individuals filling naloxone prescriptions at the start of COVID-19 pandemic, with no significant recovery observed.

FIX activity was similar in participants without and with pre-existing neutralizing antibodies.

An electronic reminding system helped identify 3783 patients with anti-HCV antibody documentation.

The low-dose cohort of RP-A501 conferred cardiac LAMP2B transgene expression.

Patients who received 2 mg or 4 mg of baricitinib maintained vIGA-AD scores through 68 weeks of treatment.